EVLO logo

Evelo Biosciences (EVLO)

Profile

Full Name

Evelo Biosciences, Inc.

Ticker Symbol

EVLO

Exchange

NASDAQ

Country

United States

IPO

May 8, 2018

Indexes

Not included

Employees

66

Key Details

Price

$0.00(0.00%)

Market cap

$9465.50(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$26.20(+43.29% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Oct 18, 23 TD Cowen
Market Perform
Jul 26, 23 Morgan Stanley
Equal-Weight
Feb 15, 23 Morgan Stanley
Equal-Weight
Nov 16, 22 Chardan Capital
Neutral
Sep 9, 22 Morgan Stanley
Equal-Weight
Aug 24, 22 Morgan Stanley
Equal-Weight
Aug 15, 22 Chardan Capital
Buy
Nov 2, 21 JMP Securities
Market Outperform
Nov 1, 21 Chardan Capital
Buy
Jun 23, 21 JMP Securities
Market Outperform

Institutional Ownership

  • What is the ticker symbol for Evelo Biosciences?
  • Does Evelo Biosciences pay dividends?
  • What sector is Evelo Biosciences in?
  • What industry is Evelo Biosciences in?
  • What country is Evelo Biosciences based in?
  • When did Evelo Biosciences go public?
  • Is Evelo Biosciences in the S&P 500?
  • Is Evelo Biosciences in the NASDAQ 100?
  • Is Evelo Biosciences in the Dow Jones?
  • When was Evelo Biosciences's last earnings report?
  • When does Evelo Biosciences report earnings?
  • Should I buy Evelo Biosciences stock now?

What is the ticker symbol for Evelo Biosciences?

The ticker symbol for Evelo Biosciences is NASDAQ:EVLO

Does Evelo Biosciences pay dividends?

No, Evelo Biosciences does not pay dividends

What sector is Evelo Biosciences in?

Evelo Biosciences is in the Healthcare sector

What industry is Evelo Biosciences in?

Evelo Biosciences is in the Biotechnology industry

What country is Evelo Biosciences based in?

Evelo Biosciences is headquartered in United States

When did Evelo Biosciences go public?

Evelo Biosciences's initial public offering (IPO) was on May 8, 2018

Is Evelo Biosciences in the S&P 500?

No, Evelo Biosciences is not included in the S&P 500 index

Is Evelo Biosciences in the NASDAQ 100?

No, Evelo Biosciences is not included in the NASDAQ 100 index

Is Evelo Biosciences in the Dow Jones?

No, Evelo Biosciences is not included in the Dow Jones index

When was Evelo Biosciences's last earnings report?

Evelo Biosciences's most recent earnings report was on Apr 7, 2025

When does Evelo Biosciences report earnings?

The date for Evelo Biosciences's next earnings report has not been announced yet

Should I buy Evelo Biosciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page